Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2) in Major Depressive Disorder (MDD)

Major Depressive Disorder Clinical Trial

Official title:

A Pilot, Phase II, Open-Label, Single-Center Study of Sodium-Glucose Cotransporter-2 Inhibitor Empagliflozin in Major Depressive Disorder

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05757791
• Other study ID #: 23-00027
• Status: Recruiting
• Phase: Phase 2
• Start date: March 17, 2023
• Est. completion date: August 2025

Study information

• Verified date: February 2024
• Source: NYU Langone Health
• Contact: Dan V Iosifescu, MD, MMSc
• Phone: (646) 754-5156
• Email: dan.iosifescu[@]nyulangone.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary purpose of this study is to determine whether empagliflozin, a medication in a class known as sodium-glucose cotransporter-2 inhibitors (SGLT2) inhibitors, may reduce symptoms of depression. Since this medication helps the body make metabolites known as ketone bodies which can serve as an alternate energy source for the brain, the investigators can also test whether ketone bodies help with depressed mood.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 16
• Est. completion date: August 2025
• Est. primary completion date: June 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Provide written informed consent, as approved by the NYU Institutional Research Ethic Board (IRB).

• Patients ages 18-65;

• Current/acute Major Depressive Disorder (MDD) diagnosis, per MINI psychiatric interview;

• At least moderate severity of depression (Montgomery-Åsberg Depression Rating Scale (MADRS) score of at least 20 at initial screen);

Exclusion Criteria:

• DSM-5 diagnosis of Bipolar disorders, Cyclothymia, Schizoaffective disorder, Schizophrenia; any psychotic disorder or affective psychosis;

• Subjects that have had more than two failures of adequate anti-depressant trials in the current MDD episode;

• Subjects on psychotropic medications other than SSRIs, NDRIs, SNRIs, or mirtazapine (occasional use of sleep agents, equivalent to lorazepam 1 mg or zolpidem 10 mg, will be allowed);

• Those that have previously been on SGLT2 inhibitors;

• A significant history of non-adherence to treatments;

• History of neurologic / seizure disorder;

• A significant history of non-adherence to treatments;

• History of dementia/cognitive dysfunction (MOCA < 22);

• A primary diagnosis of a personality disorder, in the opinion of the screening clinician;

• DSM-5 substance use disorder (drug/alcohol) active within the past 12 months, or positive urine toxicology at screening;

• History of diabetic ketoacidosis;

• History of recurrent genital mycotic infection;

• GFR <45;

• HgA1c.>8.0%

• History of an allergic reaction to an SGLT2 inhibitor.

• Pregnancy or lactation (women of reproductive age, ie <50 years old, should be on licensed hormonal or barrier method contraception).

• Any known pancreatic disease resulting in insulin deficiency (T1D, history of pancreatitis, pancreatic surgery);

• History of liver or kidney disease;

• Hypersensitivity to empagliflozin or any of the excipients in JARDIANCE.

Related Conditions & MeSH terms

• Depression
• Depressive Disorder
• Depressive Disorder, Major
• Major Depressive Disorder

Intervention

Drug:
• Empagliflozin
The full duration of therapy will be six-weeks. The route of administration will be oral. The starting dose of the medication will be 10mg daily for the first 14 days of the study, with a dose escalation to 25mg for the last 28 days of the study.

Locations

Country	Name	City	State
United States	NYU Langone Health	New York	New York

Sponsors (2)

Lead Sponsor	Collaborator
NYU Langone Health	American Society of Clinical Psychopharmacology

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Score	10-item physician-rated scale assessing depressive symptomology. Each item is rated on a Likert scale ranging from 0 to 6. The total score is the sum of responses and ranges from 0 to 60; higher scores indicate greater depressive symptomology. Specifically, a total score ranging from 0 to 6 indicates that the patient is in the normal range (no depression); a score ranging from 7 to 19 indicates "mild depression;" 20 to 34 indicates "moderate depression;" a score of 35 and greater indicates "severe depression;" and a total score of 60 or greater indicates "very severe depression."	Baseline, Week 6
Secondary	Change from Baseline in Columbia Suicide Severity Rating Scale (C-SSRS) Score	C-SSRS systematically tracks suicidal ideation and behavior. The total score range is 0 (no ideation is present) - 5 (active suicidal ideation with specific plan and intent). The higher the score, the greater one's suicidal ideation. Any score greater than 0 is important and may indicate the need for mental health intervention.	Baseline, Week 6
Secondary	Change from Baseline in Snaith-Hamilton Pleasure Scale (SHAPS) Score	14- item questionnaire assessing four domains of pleasure response, aimed as a scale to measure anhedonia, or the inability to experience pleasure. Each item is rated on a Likert scale ranging from 1 (strongly disagree) to 4 (strongly agree). The total score is the sum of responses and ranges from 14 to 56; higher scores indicate lesser anhedonia.	Baseline, Week 6